- Research article
- Open Access
- Open Peer Review
A polymorphism in the regulatory region of PRNPis associated with increased risk of sporadic Creutzfeldt-Jakob disease
© Sanchez-Juan et al; licensee BioMed Central Ltd. 2011
- Received: 3 February 2011
- Accepted: 22 May 2011
- Published: 22 May 2011
Creutzfeldt-Jakob disease (CJD) is a rare transmissible neurodegenerative disorder. An important determinant for CJD risk and phenotype is the M129V polymorphism of the human prion protein gene (PRNP), but there are also other coding and non-coding polymorphisms inside this gene.
We tested whether three non-coding polymorphism located inside the PRNP regulatory region (C-101G, G310C and T385C) were associated with risk of CJD and with age at onset in a United Kingdom population-based sample of 131 sporadic CJD (sCJD) patients and 194 controls.
We found no disease association for either PRNP C-101G or PRNP T385C. Although the crude analysis did not show a significant association between PRNP G310C and sCJD (OR: 1.5; 95%CI = 0.7 to 2.9), after adjusting by PRNP M129V genotype, it resulted that being a C allele carrier at PRNP G310C was significantly (p = 0.03) associated with a 2.4 fold increased risk of developing sCJD (95%CI = 1.1 to 5.4). Additionally, haplotypes carrying PRNP 310C coupled with PRNP 129M were significantly overrepresented in patients (p = 0.02) compared to controls. Cases of sCJD carrying a PRNP 310C allele presented at a younger age (on average 8.9 years younger than those without this allele), which was of statistical significance (p = 0.05). As expected, methionine and valine homozygosity at PRNP M129V increased significantly the risk of sCJD, alone and adjusted by PRNP G310C (OR MM/MV = 7.3; 95%CI 3.9 to 13.5 and OR VV/MV = 4.0; 95%CI 1.7 to 9.3).
Our findings support the hypothesis that genetic variations in the PRNP promoter may have a role in the pathogenesis of sCJD.
- Creutzfeldt-Jakob disease
- prion protein gene
- molecular subtype
- regulatory region
- early onset
The polymorphism coding for methionine (M) or valine (V) at codon 129 of the prion protein gene (PRNP M129V) plays a pivotal role in the susceptibility to Creutzfeldt-Jakob disease (CJD), influencing familial, transmitted and sporadic forms of the disease . Moreover, the PRNP M129V genotype, in combination with the type of disease-associated prion protein (PrPsc) deposited in the brain, is a strong modulator of the clinical phenotype of sporadic [2–6] and genetic forms  and also susceptibility to variant CJD (vCJD). All vCJD cases studied to date have been methionine homozygous at this locus . A recent genome wide association analysis performed primarily with vCJD samples showed that PRNP locus was strongly associated to disease risk across several markers, the main contribution being conferred by PRNP M129V .
Transgenic animal models [10, 11] and cattle studies [12, 13] suggest that the level of expression of PRNP has a significant influence on the incubation period of the disease. This finding has led to the hypothesis that variations in the regulatory region of PRNP, which may lead to an increased expression of the gene, may influence susceptibility and age at onset in sporadic CJD, independent of the influence of PRNP M129V. In a previous study we defined the PRNP regulatory region, and identified three infrequent single nucleotide polymorphisms (SNPs), PRNP C-101G, located upstream of the transcription start site, and two intronic SNPs: PRNP G310C and PRNP T385C. An initial association study carried out in 25 sporadic CJD (sCJD) and 77 controls showed that a subgroup that carried any of the rare alleles in the regulatory region had an increased risk for sCJD . In addition, a subsequent genetic association study performed on 45 sCJD and 117 controls found an increased risk for PRNP M129V heterozygotes carrying the PRNP -101G allele . All three regulatory region SNPs, which are within 486 bp, are included in an LD block; pair wise LD: C-101G and G310C (D' = 1), C-101G and T385C (D' = 0.94), G310C and T385C (D' = 1). Based on our initial results, we genotyped these three PRNP regulatory region SNPs in an independent population of 131 sporadic CJD patients and 194 healthy controls from the UK in order to assess association with the disease.
Cases were derived from a population-based survey of CJD in the UK carried out by the UK National CJD Surveillance Unit . Those with DNA available from 1991 to 2003 were selected for the study. Only patients with sCJD who fulfilled the WHO diagnostic criteria for definite or probable CJD were included. Definite sCJD diagnosis was based on neuropathological examination. Probable cases required an appropriate clinical profile, supported by characteristic findings on EEG or CSF 14-3-3-protein detection . Whenever possible, all EEGs were reviewed by a member of the surveillance system and scored for the presence or absence of typical or characteristic diagnostic features . The CSF 14-3-3 immunoassays were performed using Western-blotting . Randomly selected anonymous blood donors formed the control group; they were collected from two geographical areas in the UK; one in Northern Ireland (Belfast) and one in Scotland (Edinburgh). None of the cases or controls was included in the previous study. Demographical and clinical data were collected for patients. Information on PrPsc type was included in the database when available.
The three PRNP regulatory region SNPs and PRNP M129V were genotyped in cases and controls as described in a previous article . Hardy Weinberg proportions were assessed. Firstly, we tested the association between being a carrier of the rare alleles of the three PRNP regulatory region SNPs and the risk of developing the disease. Odds ratios (OR) and 95% confidence intervals (CI) were calculated using logistic regression and adjusted for PRNP M129V genotype. Secondly, using Haploview v3.2 software http://www.broad.mit.edu/mpg/haploview we assessed linkage disequilibrium (LD) between the PRNP regulatory region SNPs and PRNP M129V; haplotype frequencies were calculated and compared between cases and controls. Permutation test was used in order to control for multiple comparisons. Finally, we compared differences in age at onset between CJD cases with and without the PRNP regulatory region rare alleles associated to disease risk. Fitting a general linear model, we assessed the differences in age at disease onset between cases, carriers versus non-carriers, adjusted by the molecular subtype (the combination of PRNP M129V genotype and PrPsc type), which is a strong modulator of age at onset [4, 6].
Signed informed consent to participate in genetic research was obtained from all controls and patients relatives. The protocols of the studies were approved by the local medical ethical committees.
Overall descriptives of sporadic CJD patients (n = 131)
Gender: female (%)
Diagnosis classification: definite (%)
Mean age at onset (years) ± SD
65.6 ± 9.5
Mean duration of disease (months) ± SD
6.6 ± 7.0
Typical EEG/total EEGs (%)
Positive MRI/total MRIs (%)
Positive CSF 14.3.3 test/total tests (%)
(n = 110 (84%)) the diagnosis was neuropathologically confirmed. The molecular classification of the case cohort showed a predominance of the MM1 subtype (53%), corresponding to the classical disease phenotype [4, 6]. The most sensitive diagnostic test was the 14-3-3 immunoassay (90%).
One of the regulatory region SNPs (PRNP T385C) deviated significantly from Hardy Weinberg proportions (p < 0.001) in controls and therefore it was excluded for haplotype analysis. PRNP C-101G, PRNP C310G and PRNP M129V were all within Hardy Weinberg equilibrium in the control group (p = 0.7, p = 0.4 and p = 0.5 respectively). In the sCJD group PRNP M129V genotypic distribution deviated as expected significantly (p < 0.001) from Hardy Weinberg proportions. We found that all three SNPs were linked to PRNP M129V ( C-101G D' = 1; C310G D' = 0.57; T385C D' = 0.72).
Overall distribution of PRNP regulatory region rare alleles and risk of sporadic CJD
OR (95% CI)
OR (95% CI) *
-101G non carriers
310C non carriers
385C non carriers
Methionine and valine homozygosity at PRNP M129V increased significantly the risk of sCJD, in the crude analysis (OR MM/MV = 4.3; 95%CI 2.5 to 7.2 and OR VV/MV = 2.9; 95%CI 1.3 to 6.3) and adjusted by PRNP G310C (OR MM/MV = 7.3; 95%CI 3.9 to 13.5 and OR VV/MV = 4.0; 95%CI 1.7 to 9.3).
Distribution of PRNP 310C allele, stratified by PRNP M129V genotypes, and risk of sporadic CJD
OR (95% CI)
Mean age at onset ± standard errors of sporadic CJD patients across molecular subtypes and PRNP 310C allele distribution
PRNP 310C carriers
PRNP 310C non carriers
Mean difference (Years)
57.7 ± 8.1
67.9 ± 9.1
53.8 ± 6.9
66.2 ± 5.4
64.3 ± 10.5
64.8 ± 11.2
56.9 ± 3.8
65.8 ± 2.4
The genetics of sCJD are exceptional in that homozygotes of both PRNP M129V alleles are at increased risk of the disease. The protective effect of the PRNP codon 129 MV genotype (47.2% of the controls versus 18.3% of cases) and the predominance of the PRNP 129 MM genotype in sCJD patients (70.4% of cases) implies that the proportion of valine alleles is lower in cases (20.4%) than in controls (33.8%), therefore in our population PRNP 129 M is as expected a risk allele for sCJD.
There are two important findings in this study. Firstly, we found a significant association between the regulatory SNP PRNP G310C and the risk of sCJD. Being a carrier of the PRNP 310C allele increased the risk of developing the disease 2.4 fold. However, this association was only apparent when we adjusted for the PRNP M129V genotype. Secondly, those patients who carried the PRNP 310C allele presented with disease at an earlier age.
In agreement with our multivariate analysis, the stratified analysis of PRNP G310C across the PRNP M129V genotypes showed a trend in all three strata to a higher proportion of individuals with PRNP 310C allele in the sCJD cases than in the controls. However, the MM individual carriers of PRNP 310C presented a higher risk than the MV and VV individuals who also carried PRNP 310C (MM group OR = 7.2 versus MV group OR = 2.1 and VV group OR = 1.4), reaching nominal statistical significance (Table 3). Although the p-value for the interaction term was not statistically significant in the logistic regression model, the stratified analysis suggests a non-additive relationship between PRNP 310C and PRNP 129 M. An interaction between the effects associated to the two SNPs is in line with the fact that the PRNP 310C allele coupled PRNP 129 M is more often found (4.4 fold) in cases than in controls, and may also explain why the relationship between PRNP G310C and sCJD only becomes significant after adjustment by PRNP M129V.
We found that the PRNP G310C polymorphism may influence the age at onset of disease. Patients with sCJD carrying the PRNP 310C allele presented at an earlier age, being on average 8.9 years younger than non-carriers. This difference was of borderline statistical significance (p = 0.05). In the analysis stratified by molecular subtypes, the highest difference in age at disease onset between PRNP 310C carriers and non-carriers was found in the MM1 group which would also support the hypothesis of an interacting effect between PRNP 310C and PRNP 129 M alleles.
Our finding of an association between the PRNP G310C, which is a SNP located in the regulatory region of the gene, and an increased risk and earlier age at onset of sCJD, might suggest that the mutant PRNP 310C allele may increase the expression of PRNP. According to the stochastic protein conformational change theory, the risk of developing CJD may increase proportionally with the level of the PRNP product, the cellular prion protein (PrPC) available . This hypothesis is in line with experimental studies in animals. Transgenic mice models indicate that the level of expression of PRNP determines the length of the incubation period following inoculation with infectious material. Mice over-expressing murine Prnp have shorter incubation periods . A similar relationship is observed in mice with decreased levels of PrPC. Animals with only one functional copy of murine Prnp consistently have longer incubation periods than wild-type mice when inoculated with the same agent . In addition, a study in inbred mice has identified three loci on chromosomes 2, 11 and 12, that significantly influence the incubation period. The Prnp region in mice, located on chromosome 2, mapped for a peak lod score of 8.2. The mice studied were all identical for the PrPC amino acid sequence, suggesting that the regulatory region of this gene may play an important role in the length of the incubation period .
The molecular subtype of sCJD patients, determined by the combination of the PrPsc type (type 1 or 2A) with the PRNP M129V genotype, is a strong modulator of age at disease onset [4, 6]. For example in our cohort, in MM or MV type 1 cases the disease developed at age 67 years on average whereas the mean age at onset in VV type 1 cases was 52 years (p = 0.004). Despite these trends, in all molecular subtypes except the MV1 group (in which there were only three cases), there are cases with symptom onset at an age of less than 50 years (data not shown). This suggests that although molecular subtype is an important determinant of age at onset, there are other influencing factors. Although numbers of cases are limited in our study, it is interesting that within each molecular subtype, on average, carriers of the PRNP 310C allele are younger at onset than non-carriers.
A possible source of bias in our study is the use as controls of randomly selected anonymised blood donors who are not matched for age or sex with the patients. For example, if the distribution of the genotypes studied differed with age this would introduce bias. However, it has been published that this is not the case and the distribution of the PRNP M129V genotypes does not differ with gender or age .
We have partially replicated our previous study results  in an independent UK case control population. Our analyses offer new evidence for the association of a PRNP regulatory region SNP (PRNP 310C) with risk and earlier age at disease onset of sCJD. Although PRNP 310C is a rare allele, and is not present in the majority of patients with sCJD, our findings may offer a new insight into the elusive aetiology of CJD. The results of our study would suggest that a PRNP dosage effect could play a role in the causal pathway of sCJD. Nevertheless, we have to emphasize that these conclusions are based on the assumption that PRNP 310 is associated to PrP gene expression due to the fact that it is located inside the gene regulatory region. Therefore, functional studies to assess the effect of the PRNP 310C allele should be carried out as a test for this hypothesis.
The authors would like to thank all the families of the patients.
This study was funded by a grant no. 121-7408 from the Department of Health.
The Dutch Ministry of Health, Welfare and Sports supports the CJD surveillance in The Netherlands, which includes monitoring and scientific research.
The CJD surveillance in The Netherlands and the UK National CJD Surveillance Unit are part of the European Creutzfeldt-Jakob Disease Surveillance network (EUROCJD) which is funded by (DG SANCO) - 2003201and NeuroPrion (Network of Excellence) - FOOD CT 2004 506579.
Pascual Sanchez-Juan was supported by grant from FIS (PI080139).
- Alperovitch A, Zerr I, Pocchiari M, Mitrova E, de Pedro Cuesta J, Hegyi I, Collins S, Kretzschmar H, van Duijn C, Will RG: Codon 129 prion protein genotype and sporadic Creutzfeldt-Jakob disease. Lancet. 1999, 353: 1673-1674. 10.1016/S0140-6736(99)01342-2.View ArticlePubMedGoogle Scholar
- Sánchez-Juan P, Green A, Ladogana A, Cuadrado-Corrales N, Sánchez-Valle R, Mitrová E, Stoeck K, Sklaviadis T, Kulczycki J, Heinemann U, Hess K, Slivarichová D, Saiz A, Calero M, Mellina V, Knight R, van Duijn CM, Zerr I: CSF tests in the differential diagnosis of Creutzfeldt-Jakob disease. Neurology. 2006, 67: 637-43. 10.1212/01.wnl.0000230159.67128.00.View ArticlePubMedGoogle Scholar
- Sanchez-Juan P, Sánchez-Valle R, Green A, Ladogana A, Cuadrado-Corrales N, Mitrová E, Stoeck K, Sklaviadis T, Kulczycki J, Hess K, Krasnianski A, Equestre M, Slivarichová D, Saiz A, Calero M, Pocchiari M, Knight R, van Duijn CM, Zerr I: Influence of timing on CSF tests value for Creutzfeldt-Jakob disease diagnosis. J Neurol. 2007, 254: 901-6. 10.1007/s00415-006-0472-9.View ArticlePubMedPubMed CentralGoogle Scholar
- Collins SJ, Sanchez-Juan P, Masters CL, Klug GM, van Duijn C, Poleggi A, Pocchiari M, Almonti S, Cuadrado-Corrales N, de Pedro-Cuesta J, Budka H, Gelpi E, Glatzel M, Tolnay M, Hewer E, Zerr I, Heinemann U, Kretszchmar HA, Jansen GH, Olsen E, Mitrova E, Alpérovitch A, Brandel JP, Mackenzie J, Murray K, Will RG: Determinants of diagnostic investigation sensitivities across the clinical spectrum of sporadic Creutzfeldt-Jakob disease. Brain. 2006, 129: 2278-87. 10.1093/brain/awl159.View ArticlePubMedGoogle Scholar
- Meissner B, Kallenberg K, Sanchez-Juan P, Collie DA, Summers DM, Almonti S, Collins SJ, Smith P, Cras P, Jansen GH, Brandel JP, Coulthart MB, Roberts H, Van Everbroeck B, Galanaud D, Mellina V, Will RG, Zerr I: MRI lesion profiles in sporadic Creutzfeldt-Jakob disease. Neurology. 2009, 72: 1994-2001. 10.1212/WNL.0b013e3181a96e5d.View ArticlePubMedGoogle Scholar
- Parchi P, Giese A, Capellari S, Brown P, Schulz-Schaeffer W, Windl O, Zerr I, Budka H, Kopp N, Piccardo P, Poser S, Rojiani A, Streichemberger N, Julien J, Vital C, Ghetti B, Gambetti P, Kretzschmar H: Classification of sporadic Creutzfeldt-Jakob disease based on molecular and phenotypic analysis of 300 subjects. Ann Neurol. 1999, 46: 224-233. 10.1002/1531-8249(199908)46:2<224::AID-ANA12>3.0.CO;2-W.View ArticlePubMedGoogle Scholar
- Goldfarb LG, Petersen RB, Tabaton M, Brown P, LeBlanc AC, Montagna P, Cortelli P, Julien J, Vital C, Pendelbury WW, et al: Fatal familial insomnia and familial Creutzfeldt-Jakob disease: disease phenotype determined by a DNA polymorphism. Science. 1992, 258: 806-808. 10.1126/science.1439789.View ArticlePubMedGoogle Scholar
- Ward HJ HM, Will RG, Ironside JW: Variant Creutzfeldt-Jakob disease. Clin Lab Med. 2003, 23: 87-108. 10.1016/S0272-2712(02)00068-9.View ArticlePubMedGoogle Scholar
- Mead S, Poulter M, Uphill J, Beck J, Whitfield J, Webb TE, Campbell T, Adamson G, Deriziotis P, Tabrizi SJ, Hummerich H, Verzilli C, Alpers MP, Whittaker JC, Collinge J: Genetic risk factors for variant Creutzfeldt-Jakob disease: a genome-wide association study. Lancet Neurol. 2009, 8: 57-66. 10.1016/S1474-4422(08)70265-5.View ArticlePubMedPubMed CentralGoogle Scholar
- Westaway D, Mirenda CA, Foster D, Zebarjadian Y, Scott M, Torchia M, Yang SL, Serban H, DeArmond SJ, Ebeling C, et al: Paradoxical shortening of scrapie incubation times by expression of prion protein transgenes derived from long incubation period mice. Neuron. 1991, 7: 59-68. 10.1016/0896-6273(91)90074-A.View ArticlePubMedGoogle Scholar
- Manson JC, Clarke AR, McBride PA, McConnell I, Hope J: PrP gene dosage determines the timing but not the final intensity or distribution of lesions in scrapie pathology. Neurodegeneration. 1994, 3: 331-340.PubMedGoogle Scholar
- Sander P, Hamann H, Drögemüller C, Kashkevich K, Schiebel K, Leeb T: Bovine prion protein gene (PRNP) promoter polymorphisms modulate PRNP expression and may be responsible for differences in bovine spongiform encephalopathysusceptibility. J Biol Chem. 2005, 280: 37408-14. 10.1074/jbc.M506361200.View ArticlePubMedGoogle Scholar
- Haase B, Doherr MG, Seuberlich T, Drögemüller C, Dolf G, Nicken P, Schiebel K, Ziegler U, Groschup MH, Zurbriggen A, Leeb T: PRNP promoter polymorphisms are associated with BSE susceptibility in Swiss and German cattle. BMC Genet. 2007, 8: 15-View ArticlePubMedPubMed CentralGoogle Scholar
- McCormack JE, Baybutt HN, Everington D, Will RG, Ironside JW, Manson JC: PRNP contains both intronic and upstream regulatory regions that may influence susceptibility to Creutzfeldt-Jakob Disease. Gene. 2002, 288: 139-146. 10.1016/S0378-1119(02)00466-3.View ArticlePubMedGoogle Scholar
- Bratosiewicz-Wasik J, Liberski PP, Golanska E, Jansen GH, Wasik TJ: Regulatory sequences of the PRNP gene influence susceptibility to sporadic Creutzfeldt-Jakob disease. Neurosci Lett. 2007, 411: 163-7. 10.1016/j.neulet.2006.08.001.View ArticlePubMedGoogle Scholar
- Cousens SN, Zeidler M, Esmonde TF, De Silva R, Wilesmith JW, Smith PG, Will RG: Sporadic Creutzfeldt-Jakob disease in the United Kingdom: analysis of epidemiological surveillance data for 1970-96. Bmj. 1997, 315: 389-395.View ArticlePubMedPubMed CentralGoogle Scholar
- WHO: Human transmissible spongiform encephalopathies. Weekly Epidemiological record. 1998, 47: 361-365.Google Scholar
- Steinhoff BJ, Zerr I, Glatting M, Schulz-Schaeffer W, Poser S, Kretzschmar HA: Diagnostic value of periodic complexes in Creutzfeldt-Jakob disease. Ann Neurol. 2004, 56: 702-708. 10.1002/ana.20261.View ArticlePubMedGoogle Scholar
- Zerr I, Bodemer M, Gefeller O, Otto M, Poser S, Wiltfang J, Windl O, Kretzschmar HA, Weber T: Detection of 14-3-3 protein in the cerebrospinal fluid supports the diagnosis of Creutzfeldt-Jakob disease. Ann Neurol. 1998, 43: 32-40. 10.1002/ana.410430109.View ArticlePubMedGoogle Scholar
- Weissmann C: Molecular genetics of transmissible spongiform encephalopathies. J Biol Chem. 1999, 274: 3-6. 10.1074/jbc.274.1.3.View ArticlePubMedGoogle Scholar
- Lloyd SE, Onwuazor ON, Beck JA, Mallinson G, Farrall M, Targonski P, Collinge J, Fisher EM: Identification of multiple quantitative trait loci linked to prion disease incubation period in mice. Proc Natl Acad Sci USA. 2001, 98: 6279-6283. 10.1073/pnas.101130398.View ArticlePubMedPubMed CentralGoogle Scholar
- Nurmi MH, Bishop M, Strain L, Brett F, McGuigan C, Hutchison M, Farrell M, Tilvis R, Erkkilä S, Simell O, Knight R, Haltia M: The normal population distribution of PRNP codon 129 polymorphism. Acta Neurol Scand. 2003, 108: 374-378.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2350/12/73/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.